ELVN (US) share price forecast & AI signal — Enliven Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in ELVN
Enliven Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Enliven Therapeutics, Inc
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $49.43 |
| 2026-11-05 | $44.79 |
| 2026-11-04 | $47.25 |
| 2026-11-03 | $44.83 |
| 2026-11-02 | $44.63 |
| 2026-10-30 | $44.25 |
| 2026-10-29 | $45.08 |
ELVN FAQ
Is Enliven Therapeutics, Inc (ELVN) a buy or sell this week?
The ACE Stock Bots machine-learning model rates ELVN a SELL for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for ELVN?
Every week the model scores ELVN across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.